Despite industry-wide challenges including tightening venture funding and regulatory uncertainty, key biotech and pharma companies are adjusting strategies to sustain growth. Novartis named a new CFO and slightly raised income guidance amid a $10B share buyback initiative. Hologic secured $2.42 billion in refinancing aimed at supporting merger and acquisition activity. Thermo Fisher Scientific acquired Sanofi’s Ridgefield steriles manufacturing site to boost US capacity. Australian government awarded AU$100 million to incubators fostering local biopharma and med-tech startups. Biotech venture funding slowed notably in the first half of 2025, with private financing in life science tools and diagnostics showing mixed trends.